



(11) **EP 2 115 140 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 471/04 ^(2006.01) **A61K 31/437** ^(2006.01)
A61P 31/18 ^(2006.01) **A61P 35/00** ^(2006.01)
C12N 15/29 ^(2006.01) **C12N 15/09** ^(2006.01)
C12N 15/10 ^(2006.01)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(86) International application number:
PCT/IB2007/050322

(45) Date of publication and mention
of the grant of the patent:
30.11.2016 Bulletin 2016/48

(87) International publication number:
WO 2008/093173 (07.08.2008 Gazette 2008/32)

(21) Application number: **07705747.9**

(22) Date of filing: **31.01.2007**

(54) **Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates**

Positiv geladene wasserlösliche Arzneistoffvorstufen von 1H-Imidazo-[4,5-c]-chinolin-4-aminen und verwandten Verbindungen mit sehr hohen Hautdurchdringungsgeschwindigkeiten

Promédicaments hydrosolubles à charge positive de 1H-imidazo[4,5-c]quinolin-4-amines et composés associés a taux élevés de pénétration cutanée

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(43) Date of publication of application:
11.11.2009 Bulletin 2009/46

(60) Divisional application:
16200797.5

(73) Proprietor: **Yu, Chongxi**
Kensington, MD 20895 (US)

(72) Inventor: **Yu, Chongxi**
Kensington, MD 20895 (US)

(74) Representative: **Finnegan Europe LLP**
16 Old Bailey
London EC4M 7EG (GB)

(56) References cited:
US-A- 4 689 338 US-A- 4 698 348

- **GOBLYOS A. ET AL.: 'Structure-Activity Relationships of New 1H-Imidazo[4,5-c]quinolin-4-amines Derivatives as Allosteric Enhancers of the A3 Adenosine Receptor' J. MED. CHEM. vol. 49, 15 April 2006, pages 3354 - 3361, XP008115094**
- **JOHN F.G. ET AL.: 'Structure-Activity Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production' J. MED. CHEM. vol. 48, 21 April 2005, pages 3481 - 3491, XP008115095**
- **MARK J.B. ET AL.: '(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimization as highly potent and selective MSK-1-inhibitors' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 15, 20 May 2005, pages 3407 - 3411, XP025314186**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 115 140 B8